Goulburn Valley Health, Graham Street, Shepparton, Victoria, 3630, Australia.
Department of Rural Health, The University of Melbourne, Shepparton, Victoria, 3630, Australia.
Trials. 2022 Mar 24;23(1):231. doi: 10.1186/s13063-021-05857-7.
Rates of caesarean section (CS) delivery are increasing worldwide. CS delivery is often complicated by post-surgical infection, estimated to have ten times higher risk of infections than that of vaginal delivery. While widespread use of prophylactic antibiotics with CS has reduced post-CS infection, incidence may be reduced further by cleansing the vagina with betadine antiseptic wash prior to CS. However, reports are not consistent, and different antiseptics have been practised variably. Therefore, in order to ensure that the risks to the mother are as minimal as possible, it is important to determine whether vaginal irrigation with antiseptic wash reduces post-CS infection rate, and if so, which antiseptic is paramount.
Women giving birth by elective or emergency CS will be assigned into either the intervention (1% povidone iodine (n = 125) or chlorhexidine (n = 125)) or the control (no-irrigation (n = 125)) group by using a block randomisation technique. Participants will receive vaginal cleansing with an intervention or no vaginal cleansing prior to CS. Follow-up will occur at day 14 and day 28 post-CS. A predeveloped questionnaire will be completed with patients' socio-demographic characteristics and required clinical and pregnancy-related information. All the fever, infection and readmission-related information will be completed from either the patient's or their record or at follow-up visits. Occurrence of post-CS infection, as measured by primary and secondary outcomes, will be compared between the groups.
The results of this study may provide important data to define the future uniform use of vaginal antiseptic wash immediately prior to CS and to determine the best antiseptic wash details in reducing post-operative infections or complications.
Australian New Zealand Clinical Trials Registry (ANZCTR) ACTRN12620000971932p . Registered on 28 September 2020.
全世界剖宫产(CS)分娩率不断上升。CS 分娩常并发术后感染,其感染风险估计比阴道分娩高 10 倍。虽然广泛使用 CS 预防性抗生素已降低了 CS 后的感染率,但在 CS 前用洗必泰消毒冲洗阴道可能会进一步降低感染率。然而,报告结果并不一致,不同的消毒剂使用情况也各不相同。因此,为了将母亲的风险降到最低,重要的是要确定阴道冲洗消毒是否能降低 CS 后的感染率,如果可以,哪种消毒剂效果最佳。
采用区组随机化方法,将择期或紧急 CS 分娩的产妇分配至干预组(1%聚维酮碘(n = 125)或洗必泰(n = 125))或对照组(不冲洗(n = 125))。参与者将在 CS 前接受干预或不接受阴道冲洗消毒。在 CS 后第 14 天和第 28 天进行随访。通过预开发的问卷,收集患者的社会人口统计学特征和所需的临床和妊娠相关信息。所有发热、感染和再入院相关信息将通过患者或其病历或随访访问获得。将比较两组间 CS 后感染的发生情况(通过主要和次要结局进行测量)。
本研究结果可为明确 CS 前阴道使用消毒剂的未来统一应用提供重要数据,并确定最佳消毒剂细节以减少术后感染或并发症。
澳大利亚新西兰临床试验注册中心(ANZCTR)ACTRN12620000971932p。于 2020 年 9 月 28 日注册。